中国神经再生研究(英文版) ›› 2023, Vol. 18 ›› Issue (7): 1495-1496.doi: 10.4103/1673-5374.360319

• 观点:视神经损伤修复保护与再生 • 上一篇    下一篇

佩玛贝特,一种有效的选择性 PPARα 调节剂,一种有前途的缺血性视网膜病变新疗法?

  

  • 出版日期:2023-07-15 发布日期:2023-01-11

Pemafibrate, a potent selective peroxisome proliferator-activated receptor α modulator, a promising novel treatment for ischemic retinopathy?

Deokho Lee, Yohei Tomita, Kazuno Negishi, Toshihide Kurihara*#br#   

  1. Department of Ophthalmology, Keio University School of Medicine, Shinanomachi, Shinjuku-ku, Japan
  • Online:2023-07-15 Published:2023-01-11
  • Contact: Toshihide Kurihara, MD, PhD, kurihara@28keio.jp.
  • Supported by:
    This work was supported by the KAKENHI, Nos. 15K10881 and 18K09424 (to TK) and JST SPRING, No. JPMJSP2123 (to DL).

摘要: https://orcid.org/0000-0002-5457-2720 (Toshihide Kurihara)

Abstract: Ischemic retinopathy is a retinal disease caused by ischemic attacks. Ischemia is a common pathologic mechanism in various retinal disorders and diseases such as age-related macular degeneration, diabetic retinopathy, glaucoma, or vascular occlusion (Osborne et al., 2004). Although various murine models have been developed to understand a series of metabolic mechanisms induced by retinal ischemia and further used to test promising therapeutics, effective treatment in ischemic retinopathy has not been clearly suggested. This is associated with the notion that the contributing pathologic metabolic pathways might be enormously complex.